University of Illinois at Chicago

Accepting patients

SELECT MDS-1

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Learn more
  • Hypomethylating Agents (HMA)
  • RAR-α / NR1B1
  • Phase 3

Not yet accepting

Treosulfan and Fludarabine Pre-Transplant

An Open-label, Non-randomized, Prospective Trial to Evaluate the Effect of Renal Function Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics in Patients With AML or MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Learn more
  • Antimetabolites
  • Chemotherapy
  • Phase 1